NASDAQ:LJPC

La Jolla Pharmaceutical Stock Forecast, Price & News

$3.61

-0.10 (-2.70 %)

(As of 07/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.55

▼

$3.70

50-Day Range

$3.50

▼

$5.20

52-Week Range

$3.35

▼

$7.85

Volume76,493 shs

Average Volume575,437 shs

Market Capitalization$99.17 million

P/E RatioN/A

Dividend YieldN/A

Beta2.36

30 days | 90 days | 365 days | Advanced Chart

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Has Found A Path To Profitability
July 26, 2021 | finance.yahoo.com

La Jolla Pharmaceutical (NASDAQ:LJPC) vs. Fate Therapeutics (NASDAQ:FATE) Head-To-Head Comparison
July 23, 2021 | americanbankingnews.com

La Jolla Pharmaceutical (NASDAQ:LJPC) Short Interest Update
July 16, 2021 | americanbankingnews.com

La Jolla Pharmaceutical Company Common Stock (LJPC)
July 15, 2021 | nasdaq.com

Have Insiders Been Buying La Jolla Pharmaceutical Company (NASDAQ:LJPC) Shares?
June 26, 2021 | nasdaq.com

Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
May 18, 2021 | finance.yahoo.com

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
May 7, 2021 | finance.yahoo.com

La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
May 7, 2021 | finance.yahoo.com

Analysts Are Optimistic We'll See A Profit From La Jolla Pharmaceutical Company (NASDAQ:LJPC)
April 23, 2021 | nasdaq.com

Kidney fibrosis treatment Market Growth, Trends, Challenges, Opportunities|Hoffmann-La Roche Ltd, Pfizer, La Jolla Pharmaceutical Company
April 8, 2021 | marketwatch.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LJPC
Previous Symbol
CUSIPN/A
CIK920465
Webwww.lajollapharmaceutical.com
Phone858-207-4264
Employees59
Year FoundedN/A

Sales & Book Value

Annual Sales$33.42 million
Price / Sales2.97
Cash FlowN/A
Price / Cash FlowN/A
Book Value($3.36) per share
Price / Book-1.07

Profitability

EPS (Most Recent Fiscal Year)($1.44)
Net Income$-39,420,000.00
Net Margins-27.37%
Return on EquityN/A
Return on Assets-18.76%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares27,471,000
Market Cap$99.17 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

2.40 out of 5 stars

Medical Sector

47th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

5th out of 213 stocks

3.5 Analyst's Opinion

Consensus Rating
La Jolla Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, La Jolla Pharmaceutical has a forecasted upside of 315.5% from its current price of $3.61.
Amount of Analyst Coverage
La Jolla Pharmaceutical has received no research coverage in the past 90 days.

3.5 Community Rank

Outperform Votes
La Jolla Pharmaceutical has received 369 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
La Jolla Pharmaceutical has received 165 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
La Jolla Pharmaceutical has received 69.10% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote “Outperform” if you believe LJPC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
La Jolla Pharmaceutical does not currently pay a dividend.
Dividend Growth
La Jolla Pharmaceutical does not have a long track record of dividend growth.

5.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, La Jolla Pharmaceutical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,165,039.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
36.30% of the stock of La Jolla Pharmaceutical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.74% of the stock of La Jolla Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for La Jolla Pharmaceutical are expected to decrease by -44.74% in the coming year, from $0.38 to $0.21 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of La Jolla Pharmaceutical is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of La Jolla Pharmaceutical is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

Is La Jolla Pharmaceutical a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" La Jolla Pharmaceutical stock.
View analyst ratings for La Jolla Pharmaceutical or view top-rated stocks.

What stocks does MarketBeat like better than La Jolla Pharmaceutical?

Wall Street analysts have given La Jolla Pharmaceutical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but La Jolla Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting La Jolla Pharmaceutical?

La Jolla Pharmaceutical saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,800,000 shares, a decline of 23.1% from the June 15th total of 2,340,000 shares. Based on an average daily volume of 273,600 shares, the days-to-cover ratio is currently 6.6 days. Currently, 6.7% of the shares of the company are short sold.
View La Jolla Pharmaceutical's Short Interest.

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for La Jolla Pharmaceutical.

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing analysts' consensus estimates of $0.67 by $0.25. The biopharmaceutical company had revenue of $34.14 million for the quarter, compared to the consensus estimate of $33.40 million.
View La Jolla Pharmaceutical's earnings history.

How has La Jolla Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LJPC stock has decreased by 24.9% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for LJPC?

1 Wall Street analysts have issued 12 month price objectives for La Jolla Pharmaceutical's shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate La Jolla Pharmaceutical's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 315.5% from the stock's current price.
View analysts' price targets for La Jolla Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the following people:

Mr. Larry G. Edwards, Pres, CEO & Director (Age 49, Pay $749.17k)
Mr. Michael S. Hearne, CFO & Sec. (Age 58, Pay $186.04k)
Dr. Lakhmir S. Chawla, Consultant (Age 50, Pay $478.97k)
Ms. Paula Rusu, VP of Operations
Ms. Sandra Vedrick, Sr. Director of Investor Relations & HR
Mr. Thomas Ouellette, VP of Sales & Marketing
Mr. Luke Seikkula, Sr. VP of Pharmaceutical Operations (Age 57)
Mr. Stewart M. Kroll, Chief Devel. Officer (Age 62)
Mr. Mark D. Williams, Sr. VP of Medical Affairs

What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO?

8 employees have rated La Jolla Pharmaceutical CEO George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among La Jolla Pharmaceutical's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of La Jolla Pharmaceutical's key competitors?

Some companies that are related to La Jolla Pharmaceutical include Outlook Therapeutics (OTLK), Ikena Oncology (IKNA), Autolus Therapeutics (AUTL), Athira Pharma (ATHA), Codiak BioSciences (CDAK), SQZ Biotechnologies (SQZ), Gritstone bio (GRTS), Orchard Therapeutics (ORTX), CEL-SCI (CVM), Fusion Pharmaceuticals (FUSN), Opthea (OPT), Harpoon Therapeutics (HARP), Black Diamond Therapeutics (BDTX), Solid Biosciences (SLDB) and AVROBIO (AVRO).
View all of LJPC's competitors.

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $3.61.

How much money does La Jolla Pharmaceutical make?

La Jolla Pharmaceutical has a market capitalization of $99.17 million and generates $33.42 million in revenue each year. The biopharmaceutical company earns $-39,420,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does La Jolla Pharmaceutical have?

La Jolla Pharmaceutical employs 59 workers across the globe.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com.

Where are La Jolla Pharmaceutical's headquarters?

La Jolla Pharmaceutical is headquartered at 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]

This page was last updated on 7/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here